Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. 2001

K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.

Immune reconstitution is an important component of successful allogeneic bone marrow transplantation. Immune reconstitution was evaluated for 5 years after transplantation. While the number of CD8+ T cells and CD56+ cells recovered early post transplantation, a low number of CD4+ and CD4+ CD45RA+ T cells and reversal of the CD4/CD8 ratio continued up to 5 years. Although early recovery of IgG and IgM was seen at day 100 post transplantation, serum concentration of IgA was below the normal range at 6 months and increased gradually up to 5 years. Development of acute GVHD did not affect the numbers of CD4+, CD8+, CD4+ CD45RA+ and CD4+ CD29+ T cells, but the number of CD56+ cells in patients who developed grades II-IV acute GVHD was low. The number of CD4+ CD29+ T cells had a tendency to be higher in the patients with extensive chronic GVHD than in those without chronic GVHD 2 years after transplantation whereas the number of CD4+ CD45RA+ T cells was low in spite of the absence of chronic GVHD. Serum concentration of IgA was lower in patients with extensive chronic GVHD than in those without chronic GVHD at 180 days. The number of CD4+ CD45RA+ cells in 10-19-year-old patients was higher than that in 40-49-year-old patients. Response to the Con A and PHA in 10-19-year-old patients was higher than that in older patients at 1 and 2 years. There was no significant difference in the ability of immune reconstitution between related transplant recipients and unrelated transplant recipients. These results suggest that chronic GVHD and age of patients affected immune reconstitution post transplant.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008934 Mitogens Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) Mitogen,Phytomitogen,Phytomitogens
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
January 2005, Blood,
K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
April 2000, Transplantation,
K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
October 1989, Histopathology,
K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
June 1989, Cancer treatment reviews,
K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
July 2014, Cytotherapy,
K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
December 1988, Blood,
K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
June 2011, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
September 2000, Human immunology,
K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
June 1985, The Tokai journal of experimental and clinical medicine,
K Fujimaki, and A Maruta, and M Yoshida, and F Kodama, and M Matsuzaki, and S Fujisawa, and H Kanamori, and Y Ishigatsubo
November 1993, Bone marrow transplantation,
Copied contents to your clipboard!